Accelerate the market transformation of innovation achievements

Source: Medical observer report 2015-07-31: China is a pharmaceutical power rather than a pharmaceutical power, with 96% of generic drugs Due to the lack of effective mechanisms and operational entities, the successful conversion rate of innovative drugs in China is less than 2%, far lower than 20% in the United States At present, China's innovation level is mainly in the stage from generic drugs to combination of generic drugs Most of the new drugs on the market are me too drugs, and the new drug market is monopolized by large international companies However, with the change of social economy and life style, the disease spectrum of our country has changed greatly There are not only diseases in developing countries, but also diseases in developing countries 90% of more than 4500 diseases are incurable For example, the incidence of mental illness in China is 15%, becoming the number one killer of health The mortality rate of malignant tumor is the first, and the incidence rate of diabetes mellitus is significantly higher and younger Therefore, inclusive innovative medicine is the rigid demand of people's health and social development In addition to technical factors, the key problems faced by innovative drugs in China are: first, scientific supervision, too long time for clinical access, and weak process management The United States is lenient in entering and strict in going out, and the enterprises are responsible for it; China is strict in going in However, the original registration of new drugs in China was tied to production, and now the drug regulatory bureau has begun to consider separating the two; second, the source innovation ability is not strong, the transformation ability is not strong, and the role of research platform and advanced productivity alliance needs to be played; third, private capital is unwilling to invest, and the early research and development support is insufficient; fourth, innovative drugs cannot enter the medical insurance or bidding procurement catalogue in time, and Market bidding procurement cycle is too long, the process of each province is not uniform In order to promote the market transformation of innovation achievements, we need to work hard on the following aspects: first, the government continues to increase investment in early R & D innovation through the dual mode of research funding and market transformation operation of early venture capital fund, taking into account the government orientation and market mechanism 2、 Build a complete investment value chain of biomedical industry, contact the upstream and downstream industry investment teams, establish an investment chain with angel / government early investment and scientific research funding, innovative drug venture capital fund, late private fund and mutual support of industrial giants to achieve sustainable capital support and industrialization promotion 3、 First of all, we are committed to realizing the phased embodiment of innovation value, realizing the company's value-added and early investment exit in the early important links of drug development, creating a successful business model case, so as to create an investment atmosphere for early innovation projects 4、 Strengthen the close cooperation between domestic and foreign innovation and R & D enterprises and production enterprises, help innovation and R & D enterprises establish or seek appropriate industrialization platform through various resources, and promote them to win market success from the success of R & D 5、 In line with the global trend of pharmaceutical research and development, we will encourage cooperation with multinational pharmaceutical groups to bring international cutting-edge technology and innovation capabilities to China's biomedical industry (sang Guowei)